FIXX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
FIXX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Homology Medicines's Enterprise Value is $-78.32 Mil. Homology Medicines's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-92.10 Mil. Therefore, Homology Medicines's EV-to-EBIT for today is 0.85.
The historical rank and industry rank for Homology Medicines's EV-to-EBIT or its related term are showing as below:
During the past 8 years, the highest EV-to-EBIT of Homology Medicines was 2.01. The lowest was -14.16. And the median was -1.97.
Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Homology Medicines's Enterprise Value for the quarter that ended in Dec. 2023 was $-46.06 Mil. Homology Medicines's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-92.10 Mil. Homology Medicines's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 199.96%.
The historical data trend for Homology Medicines's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Homology Medicines Annual Data | |||||||||||||||||
Trend | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
EV-to-EBIT | Get a 7-Day Free Trial | -6.11 | -2.81 | -0.79 | 0.55 | 0.50 |
Homology Medicines Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
EV-to-EBIT | Get a 7-Day Free Trial | 0.55 | 0.50 | 0.38 | 0.06 | 0.50 |
For the Biotechnology subindustry, Homology Medicines's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Homology Medicines's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Homology Medicines's EV-to-EBIT falls into.
Homology Medicines's EV-to-EBIT for today is calculated as:
EV-to-EBIT | = | Enterprise Value (Today) | / | EBIT (TTM) |
= | -78.316 | / | -92.102 | |
= | 0.85 |
Homology Medicines's current Enterprise Value is $-78.32 Mil.
Homology Medicines's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-92.10 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Homology Medicines (NAS:FIXX) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.
Homology Medicines's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:
Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 ) | = | EBIT | / | Enterprise Value (Q: Dec. 2023 ) |
= | -92.102 | / | -46.06040864 | |
= | 199.96 % |
Homology Medicines's Enterprise Value for the quarter that ended in Dec. 2023 was $-46.06 Mil.
Homology Medicines's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-92.10 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Homology Medicines's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.
Paul Alloway | officer: See Remarks | C/O HOMOLOGY MEDICINES, INC., 45 WIGGINS AVENUE, BEDFORD MA 01730 |
Albert Seymour | officer: Chief Scientific Officer | C/O HOMOLOGY MEDICINES, INC., ONE PATRIOTS PARK, BEDFORD MA 01730 |
Julie Jordan | officer: Chief Medical Officer | C/O HOMOLOGY MEDICINES, INC., ONE PATRIOTS PARK, BEDFORD MA 01730 |
Michael Lee Blum | officer: Chief Commercial Officer | C/O HOMOLOGY MEDICINES, INC., 45 WIGGINS AVENUE, BEDFORD MA 01730 |
W Bradford Smith | officer: CFO, Treasurer & Secretary | C/O HOMOLOGY MEDICINES, INC., ONE PATRIOTS PARK, BEDFORD MA 01730 |
Arthur Tzianabos | director, officer: President & CEO | C/O HOMOLOGY MEDICINES, INC., ONE PATRIOTS PARK, BEDFORD MA 01730 |
Timothy P Kelly | officer: See Remarks | C/O HOMOLOGY MEDICINES, INC., ONE PATRIOTS PARK, BEDFORD MA 01730 |
Gabriel Cohn | officer: Chief Medical Officer | C/O HOMOLOGY MEDICINES, INC., ONE PATRIOTS PARK, BEDFORD MA 01730 |
Kush Parmar | director, 10 percent owner | C/O 5AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107 |
5am Ventures Iv, L.p. | 10 percent owner | 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107 |
Jeffrey V. Poulton | director | 300 THIRD STREET, CAMBRIDGE MA 02142 |
James E Flynn | director, 10 percent owner, other: *Director by Deputization | 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017 |
Alise Reicin | director | C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901 |
Siyamak Rasty | officer: Chief Operating Officer | C/O HOMOLOGY MEDICINES, INC., ONE PATRIOTS PARK, BEDFORD MA 01730 |
Vida Ventures, Llc | 10 percent owner | 40 BROAD STREET, SUITE 201, BOSTON MA 02109 |
From GuruFocus
By PRNewswire • 08-16-2023
By PRNewswire PRNewswire • 07-15-2022
By Marketwired • 08-14-2023
By PRNewswire • 11-16-2023
By PRNewswire PRNewswire • 07-13-2022
By Marketwired • 07-27-2023
By PRNewswire • 11-21-2023
By PRNewswire PRNewswire • 07-12-2022
By PRNewswire PRNewswire • 07-15-2022
By sperokesalga sperokesalga • 05-11-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.